CZ286633B6 - Farmaceutické přípravky pro prevenci a léčbu rakovinových chorob a způsob jejich přípravy - Google Patents

Farmaceutické přípravky pro prevenci a léčbu rakovinových chorob a způsob jejich přípravy Download PDF

Info

Publication number
CZ286633B6
CZ286633B6 CZ19951773A CZ177395A CZ286633B6 CZ 286633 B6 CZ286633 B6 CZ 286633B6 CZ 19951773 A CZ19951773 A CZ 19951773A CZ 177395 A CZ177395 A CZ 177395A CZ 286633 B6 CZ286633 B6 CZ 286633B6
Authority
CZ
Czechia
Prior art keywords
acid
cells
compositions
composition
vitamin
Prior art date
Application number
CZ19951773A
Other languages
Czech (cs)
English (en)
Other versions
CZ177395A3 (en
Inventor
Gyula Kulcsár
Original Assignee
Immunal Kft.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunal Kft. filed Critical Immunal Kft.
Publication of CZ177395A3 publication Critical patent/CZ177395A3/cs
Publication of CZ286633B6 publication Critical patent/CZ286633B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CZ19951773A 1993-11-09 1994-11-08 Farmaceutické přípravky pro prevenci a léčbu rakovinových chorob a způsob jejich přípravy CZ286633B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them

Publications (2)

Publication Number Publication Date
CZ177395A3 CZ177395A3 (en) 1996-01-17
CZ286633B6 true CZ286633B6 (cs) 2000-05-17

Family

ID=10984131

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19951773A CZ286633B6 (cs) 1993-11-09 1994-11-08 Farmaceutické přípravky pro prevenci a léčbu rakovinových chorob a způsob jejich přípravy

Country Status (18)

Country Link
EP (1) EP0679081B1 (fr)
JP (1) JPH08508045A (fr)
KR (1) KR100363779B1 (fr)
CN (1) CN1128615C (fr)
AT (1) AT408414B (fr)
AU (1) AU682735B2 (fr)
CA (1) CA2151826C (fr)
CH (1) CH686867A5 (fr)
CZ (1) CZ286633B6 (fr)
DE (2) DE4498692T1 (fr)
ES (1) ES2094702B1 (fr)
FI (1) FI953369A7 (fr)
HU (1) HU213677B (fr)
NL (1) NL195007C (fr)
PL (1) PL177981B1 (fr)
RU (1) RU2138257C1 (fr)
SE (1) SE521049C2 (fr)
WO (1) WO1995013061A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
WO1998039013A1 (fr) * 1997-03-04 1998-09-11 Peregrine Pharmaceutical, Inc. Composition et procede de traitement du cancer et de troubles immunologiques debouchant sur des etats chroniques
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
RU2188458C2 (ru) * 2001-07-24 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ определения дозы этанола в эксперименте для инъекционной терапии опухолей печени
WO2003030890A1 (fr) * 2001-10-05 2003-04-17 Tetsuro Asao Activateurs du systeme immunitaire
EP1583543A4 (fr) * 2002-01-16 2009-09-09 Eliezer Rapaport Procedes et compositions therapeutiques pour le traitement d'un cancer avance
RU2232027C2 (ru) * 2002-10-07 2004-07-10 Новосибирская государственная медицинская академия Способ лечения псевдоэрозии шейки матки с использованием локорегионарной цитокинотерапии
RU2245143C2 (ru) * 2002-12-27 2005-01-27 Хохлов Александр Петрович Аминокислотный препарат, обладающий противоопухолевым действием, и способ его получения
RU2361583C2 (ru) * 2003-10-03 2009-07-20 Вейлен Н.В. Применение соединений, способных повышать уровень igf-1 в сыворотке крови, при приготовлении терапевтической композиции для лечения стадий различных заболеваний, ассоциированных со снижением уровня igf-1 в сыворотке людей и животных
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
WO2007026996A1 (fr) * 2005-08-03 2007-03-08 National Cancer Center Glucosamine et ses derives utilises comme inhibiteurs de la transglutaminase
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
WO2015137383A1 (fr) * 2014-03-11 2015-09-17 味の素株式会社 Adjuvant pour chimiothérapie anticancéreuse
CN110870914A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素的应用以及包含它的药物组合物
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (fr) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
ATE54826T1 (de) * 1985-10-23 1990-08-15 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
DE69229910T2 (de) * 1991-10-07 2000-04-20 Otsuka Pharmaceutical Factory, Inc. Enterale zubereitungen zur krebstherapie
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
RU2061480C1 (ru) * 1992-06-26 1996-06-10 Нонна Дмитриевна Кислякова Противоопухолевое средство (варианты)

Also Published As

Publication number Publication date
SE9502474L (sv) 1995-07-06
FI953369A0 (fi) 1995-07-07
NL9420013A (nl) 1995-10-02
JPH08508045A (ja) 1996-08-27
CN1116406A (zh) 1996-02-07
PL177981B1 (pl) 2000-02-29
DE4498692T1 (de) 1996-02-22
HU9303171D0 (en) 1994-01-28
DE69429806T2 (de) 2002-09-12
EP0679081A1 (fr) 1995-11-02
CA2151826C (fr) 2008-06-17
CA2151826A1 (fr) 1995-05-18
KR100363779B1 (ko) 2003-03-06
ATA900894A (de) 2001-04-15
CZ177395A3 (en) 1996-01-17
SE521049C2 (sv) 2003-09-23
WO1995013061A1 (fr) 1995-05-18
RU2138257C1 (ru) 1999-09-27
HU213677B (en) 1997-12-29
FI953369L (fi) 1995-07-07
EP0679081B1 (fr) 2002-02-06
CN1128615C (zh) 2003-11-26
CH686867A5 (de) 1996-07-31
AU1074995A (en) 1995-05-29
DE69429806D1 (de) 2002-03-21
AT408414B (de) 2001-11-26
AU682735B2 (en) 1997-10-16
ES2094702B1 (es) 1998-02-16
FI953369A7 (fi) 1995-09-06
SE9502474D0 (sv) 1995-07-06
NL195007C (nl) 2003-06-10
PL309600A1 (en) 1995-10-30
ES2094702A1 (es) 1997-01-16

Similar Documents

Publication Publication Date Title
CZ286633B6 (cs) Farmaceutické přípravky pro prevenci a léčbu rakovinových chorob a způsob jejich přípravy
MXPA05003431A (es) Quimioterapia de combinacion.
NZ510504A (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
CZ74698A3 (cs) Použití derivátů pyrimidinu samotných nebo v kombinaci s jinými terapeutickými opatřeními k prevenci rakoviny
WO1994016687A1 (fr) Utilisation de la creatine ou d'analogues de la creatine pour la preparation d'un medicament qui empeche la croissance des tumeurs
KR20070088653A (ko) 에포틸론 및 단백질 티로신 키나제 억제제를 포함하는조합물 및 그의 제약상 용도
MX2008016125A (es) Compuestos organicos.
EP1401431A2 (fr) Antagonistes de l'hormone de croissance humaine
Lynch et al. Treatment of mouse neoplasms with high doses of tubercidin
KR20050106119A (ko) 항종양 효과 증강제 및 항종양제
KR20040078123A (ko) 에포틸론 및 대사길항물질을 포함하는 조합물
CN101346137A (zh) 含有孔布勒塔斯塔坦与抗癌剂的组合物
JPS63316722A (ja) インターフェロンの腫瘍成長抑制作用増強剤
UA82564C2 (uk) Антиретровірусна фармацевтична композиція керованого вивільнення та спосіб її виготовлення
JPS5849315A (ja) 抗腫瘍剤
SK9342002A3 (en) Combination chemotherapy
Moertel et al. IN PATIENTS WITH GASTROINTESTINAL CARCINOMA 1, 2, 3
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
EP1485090B1 (fr) Melanges comprenant un derive d'epothilone et une imidazotetrazinone
JPH07324035A (ja) 滑膜細胞増殖抑制剤及び慢性関節リウマチ治療剤
US20220313718A1 (en) New therapy and new therapeutic agent for blood cancer
JPS59112919A (ja) 細胞静止作用を有する協力効果組成物
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用
CA1319107C (fr) Compositions empechant le transport de glucose
CN121550252A (zh) 双二羧酸二氨络铂抗癌药物

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20141108